Synbiotic Supplementation Improves Quality of Life and Inmunoneuroendocrine Response in Patients with Fibromyalgia: Influence of Codiagnosis with Chronic Fatigue Syndrome. — CFSMEATLAS
Synbiotic Supplementation Improves Quality of Life and Inmunoneuroendocrine Response in Patients with Fibromyalgia: Influence of Codiagnosis with Chronic Fatigue Syndrome.
Hinchado, María Dolores, Quero-Calero, Carmen Daniela, Otero, Eduardo et al. · Nutrients · 2023 · DOI
Quick Summary
This study tested whether a probiotic supplement (containing beneficial bacteria) could help women with fibromyalgia, especially those who also had ME/CFS. After one month of taking the supplement, participants reported feeling less stressed, anxious, and depressed, and their quality of life improved. The supplement also appeared to help their body's stress response system work better.
Why It Matters
Many ME/CFS patients experience overlapping fibromyalgia symptoms and lack effective treatments beyond symptom management. If synbiotics can improve immune dysregulation and stress-response abnormalities—both hallmark features of ME/CFS—this represents a potential low-risk intervention worth further investigation in dedicated ME/CFS populations.
Observed Findings
Participants reported decreased perceived stress, anxiety, and depression after one month of synbiotic supplementation.
Synbiotic intervention was associated with elevated cortisol release consistent with HPA-axis activation.
Quality of life during daily activities improved in the treatment group.
No detrimental changes in body composition or sleep parameters were observed.
Participants without ME/CFS codiagnosis showed greater response than those with FM+CFS.
Inferred Conclusions
Synbiotic supplementation may help restore dysregulated immune-neuroendocrine interactions in fibromyalgia, particularly in patients without concurrent ME/CFS.
The observed improvements in psychological symptoms and quality of life may reflect normalization of inflammatory-stress signaling via the cytokine-HPA axis.
Synbiotics appear to be safe in this short-term context, with no observed harms to metabolic or sleep parameters.
Remaining Questions
Does synbiotic supplementation produce similar benefits in primary ME/CFS patients not diagnosed with fibromyalgia?
What is the mechanism by which synbiotics improve HPA-axis function—direct bacterial metabolite effects, intestinal barrier restoration, or other pathways?
What This Study Does Not Prove
This study does not prove synbiotics are effective as a standalone treatment for ME/CFS; it examined mostly fibromyalgia patients with optional CFS codiagnosis, so findings may not generalize to primary ME/CFS. The observational design without placebo control cannot exclude placebo effects or confounding factors. One month is too short to determine long-term safety or sustained efficacy.
Do benefits persist beyond one month, and what is the optimal duration and dosing schedule?
Why did FM patients with CFS codiagnosis show less improvement than FM-only patients, and does this reflect different gut microbiome signatures or disease biology?